Advances in hepatitis immunization (A, B, E): Public health policy and novel vaccine delivery

Current Opinion in Infectious Diseases

Volumn 25, Issue 5, 2012, Pages 578-583

  Hendrickx, Greet ^a   Vorsters, Alex ^a   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

hepatitis A; hepatitis B; hepatitis E; vaccine

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; HEALIVE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS E VACCINE; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE POLICY; HEPATITIS A; HEPATITIS B; HEPATITIS E; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PUBLIC HEALTH; REVIEW; WORLD HEALTH ORGANIZATION;

HEALTH POLICY; HEPATITIS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNIZATION PROGRAMS; VACCINATION; VACCINES, COMBINED; VIRAL HEPATITIS VACCINES; WORLD HEALTH;

EID: 84865862223     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328357e65c     Document Type: Review

References (35)

1. Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011; 83:1885-1891.
2. Van Herck K, Crasta PD, Messier M, et al. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccine Immunother 2012; 8:323-327.
3. WHO. The immunological basis for immunization. Module 18: hepatitis A; 2011. http://www.who.int/immunization/documents/ISBN-978-92-4-150142-2/en/index. html. [Accessed 21 June 2012]
4. Crum-Cianflone NF, Wilkins K, Lee AW, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011; 203:1815-1823.
5. Iwarson S, Lindh M, Widerstrom L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004; 11:120-121.
6. Hatz C, van der Ploeg R, Beck BR, et al. Successful memory response following a booster dose with a virosome-formulated hepatitis A vaccine delayed up to 11 years. Clin Vaccine Immunol 2011; 18:885-887.
7. Sari S, Dalgic B, Basturk B, et al. Immunogenicity of hepatitis A vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr 2011; 53:532-535.
8. Radzikowski A, Banaszkiewicz A, Lazowska-Przeorek I, et al. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:1117-1124.
9. Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines co-administered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age. Pediatr Infect Dis J 2012; 31:e133-e140
10. Rinderknecht S, Michaels MG, Blatter M, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measlesmumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J 2011; 30:e179-e185.
11. Zhang ZL, Zhu XJ, Wang X, et al. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children. Vaccine 2012; 30: 4028-4033.
12. WHO. Meeting of the Strategic Advisory Group of Experts on immunization. April Wkly Epidemiol Rec [serial on the Internet]. 2012; 87. http://www.who.int/wer/2012/wer8721/en/index.html. [Accessed 21 June 2012]
13. Cervio G, Trentadue J, D'Agostino D, et al. Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program. Hepatic Med: Evidence Res 2011; 3:99-106.
14. Vacchino MN. Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat 2008; 15 (Suppl 2):47-50.
15. Pavio N, Mansuy JM. Hepatitis E in high-income countries. Curr Opin Infect Dis 2010; 23:521-527.
16. Teshale EH, Hu DJ. Hepatitis E: epidemiology and prevention. World J Hepatol 2011; 3:285-291.
17. Wierzba TF, Panzner U. Report on the International Symposium on Hepatitis E. Seoul, South Korea; 2010. Emerg Infect Dis 2012; 18. doi: 10.3201/eid1805.111916
18. Kamili S. Toward the development of a hepatitis E vaccine. Virus Res 2011; 161:93-100.
19. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895-903.
20. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895-902.
21. Wu T, Zhu FC, Huang SJ, et al. Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 2012; 55:2038.
22. Sarin SK, Kumar M. A vaccine for hepatitis E: has it finally arrived? Gastroenterology 2011; 140:1349-1352; discussion 52-53.
23. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012; 142:1388-1397; e1.
24. Aggarwal R. Hepatitis E: historical, contemporary and future perspectives. J Gastroenterol Hepatol 2011; 26 (Suppl 1):72-82.
25. FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Vaccine 2010; 28:583-588.
26. Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 2011; 10:417-427.
27. Dhillon S, Moore C, Li SD, et al. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination nonresponders with chronic liver disease. Dig Dis Sci 2012; 57:215-220.
28. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503.
29. Pniewski T, Kapusta J, Bociag P, et al. Plant expression, lyophilisation and storage of HBV medium and large surface antigens for a prototype oral vaccine formulation. Plant Cell Rep 2012; 31:585-595.
30. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011; 53:68-75.
31. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011; 18:369-375.
32. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-1396.
33. Spada E, Tosti ME, Zuccaro O, et al. Evaluation of the compliance with the protocol for preventing perinatal hepatitis B infection in Italy. J Infect 2011; 62:165-171.
34. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitisBin children 25 years after a hepatitisBNewborn and Catch-Up Immunization Program. Hepatology 2011; 54:801-807.
35. WHO. Hepatitis B vaccines.WHOposition paper. Wkly Epidemiol Rec [serial on the Internet]. 2009; 84. http://www.who.int/wer/2009/wer8440/en/index.html. [Accessed 21 June 2012]